Status:
COMPLETED
Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
Lead Sponsor:
University Hospital, Limoges
Collaborating Sponsors:
Ipsen
Conditions:
Lymphocele
Eligibility:
FEMALE
18-80 years
Phase:
PHASE3
Brief Summary
Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study
Detailed Description
Patients will be recruited among patient refered to our department for a breast cancer and needing an axillary dissection. Enrolled patients will have an injection of Lanreotide or placebo the day bef...
Eligibility Criteria
Inclusion
- Adult patient (\> 18 years),
- Patient undergoing an axillary lymphadenectomy for breast cancer
- Patient giving her agreement after being informed
Exclusion
- Patients that don't understand the trial
- Type 2 diabetic patients
- Cyclosporine treatment
- Biliary lithiasis
- Pregnancy or breast feeding
- Allergic reaction to Lanréotide or same class treatments
- Patient included in another trial within the last 30 days
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT00630695
Start Date
March 1 2008
End Date
December 1 2011
Last Update
January 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Mère Enfant- CHU de Limoges
Limoges, France, 87042